Riboflavin and amotosalen photochemical treatments of platelet concentrates reduce thrombus formation kinetics in vitro

Vox Sanguinis

Volumn 108, Issue 4, 2015, Pages 328-339

  Van Aelst, B ^a   Feys, H B ^a   Devloo, R ^a   Vanhoorelbeke, K ^b   Vandekerckhove, P ^a,b   Compernolle, V ^a,c  

^a Rode Kruis Vlaanderen   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c GHENT UNIVERSITY   (Belgium)

Author keywords

Blood components; Pathogen inactivation; Platelet concentrates; Platelet function

Indexed keywords

AMOTOSALEN; COLLAGEN; ETHANOLAMINE; FIBRINOGEN RECEPTOR; INTEGRIN; PADGEM PROTEIN; PHOSPHATIDYLSERINE; PHOTOSENSITIZING AGENT; RIBOFLAVIN; RISTOCETIN; THROMBOCYTE CONCENTRATE; TIROFIBAN; VON WILLEBRAND FACTOR; BETA3 INTEGRIN; FUROCOUMARIN DERIVATIVE;

ARTICLE; BLOOD CLOTTING; BLOOD COMPONENT; BLOOD STORAGE; CONTROLLED STUDY; FLOW CYTOMETRY; GAMMA IRRADIATION; HUMAN; HUMAN CELL; ILLUMINATION; IN VITRO STUDY; LIGHT; METABOLIC PARAMETERS; MICROFLUIDICS; PATHOGEN REDUCTION SYSTEM; PHOTOCHEMISTRY; PHOTOSENSITIZATION; PRIORITY JOURNAL; SHEAR FLOW; SHEAR STRESS; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; THROMBUS; ULTRAVIOLET RADIATION; BLOOD; DRUG EFFECTS; METABOLISM; RADIATION RESPONSE; THROMBOCYTE; THROMBOSIS;

BLOOD PLATELETS; COLLAGEN; FUROCOUMARINS; HUMANS; INTEGRIN BETA3; PHOTOSENSITIZING AGENTS; PLATELET ACTIVATION; PLATELET AGGREGATION; RIBOFLAVIN; THROMBOSIS; ULTRAVIOLET RAYS; VON WILLEBRAND FACTOR;

EID: 84927910657     PISSN: 00429007     EISSN: 14230410     Source Type: Journal    
DOI: 10.1111/vox.12231     Document Type: Article

References (39)

1. Pelletier JP, Transue S, Snyder EL: Pathogen inactivation techniques. Best Pract Res Clin Haematol 2006; 19:205-242
2. Seltsam A, Muller TH: UVC irradiation for pathogen reduction of platelet concentrates and plasma. Transfus Med Hemother 2011; 38:43-54
3. Goodrich RP: The use of riboflavin for the inactivation of pathogens in blood products. Vox Sang 2000; 78(Suppl. 2):211-215
4. Lin L, Cook DN, Wiesehahn GP, et al.: Photochemical inactivation of viruses and bacteria in platelet concentrates by use of a novel psoralen and long-wavelength ultraviolet light. Transfusion 1997; 37:423-435
5. Feys HB, Van Aelst B, Devreese K, et al.: Oxygen removal during pathogen inactivation with riboflavin and UV light preserves protein function in plasma for transfusion. Vox Sang 2014; 106:307-315
6. Kumar V, Lockerbie O, Keil SD, et al.: Riboflavin and UV-light based pathogen reduction: extent and consequence of DNA damage at the molecular level. Photochem Photobiol 2004; 80:15-21
7. Dardare N, Platz MS: Binding affinities of commonly employed sensitizers of viral inactivation. Photochem Photobiol 2002; 75:561-564
8. Johnson L, Winter KM, Reid S, et al.: The effect of pathogen reduction technology (Mirasol) on platelet quality when treated in additive solution with low plasma carryover. Vox Sang 2011; 101:208-214
9. Picker SM, Tauszig ME, Gathof BS: Cell quality of apheresis-derived platelets treated with riboflavin-ultraviolet light after resuspension in platelet additive solution. Transfusion 2012; 52:510-516
10. Jansen GA, van Vliet HH, Vermeij H, et al.: Functional characteristics of photochemically treated platelets. Transfusion 2004; 44:313-319
11. Apelseth TO, Bruserud O, Wentzel-Larsen T, et al.: In vitro evaluation of metabolic changes and residual platelet responsiveness in photochemical treated and gamma-irradiated single-donor platelet concentrates during long-term storage. Transfusion 2007; 47:653-665
12. Hechler B, Ohlmann P, Chafey P, et al.: Preserved functional and biochemical characteristics of platelet components prepared with amotosalen and ultraviolet A for pathogen inactivation. Transfusion 2013; 53:1187-1200
13. Westein E, de Witt S, Lamers M, et al.: Monitoring in vitro thrombus formation with novel microfluidic devices. Platelets 2012; 23:501-509
14. Roest M, Reininger A, Zwaginga JJ, et al.: Flow chamber-based assays to measure thrombus formation in vitro: requirements for standardization. J Thromb Haemost 2011; 9:2322-2324
15. Sakakibara M, Goto S, Eto K, et al.: Application of ex vivo flow chamber system for assessment of stent thrombosis. Arterioscler Thromb Vasc Biol 2002; 22:1360-1364
16. Andre P, LaRocca T, Delaney SM, et al.: Anticoagulants (thrombin inhibitors) and aspirin synergize with P2Y12 receptor antagonism in thrombosis. Circulation 2003; 108:2697-2703
17. Bossavy JP, Thalamas C, Sagnard L, et al.: A double-blind randomized comparison of combined aspirin and ticlopidine therapy versus aspirin or ticlopidine alone on experimental arterial thrombogenesis in humans. Blood 1998; 92:1518-1525
18. Broos K, Feys HB, De Meyer SF, et al.: Platelets at work in primary hemostasis. Blood Rev 2011; 25:155-167
19. van Marwijk Kooy M, Akkerman JW, vanAsbeck S, et al.: UVB radiation exposes fibrinogen binding sites on platelets by activating protein kinase C via reactive oxygen species. Br J Haematol 1993; 83:253-258
20. Zeddies S, De Cuyper IM, van der Meer PF, et al.: Pathogen reduction treatment using riboflavin and ultraviolet light impairs platelet reactivity toward specific agonists in vitro. Transfusion 2014; 54:2292-2300
21. Terada C, Mori J, Okazaki H, et al.: Effects of riboflavin and ultraviolet light treatment on platelet thrombus formation on collagen via integrin alphaIIbbeta3 activation. Transfusion 2014; 54:1808-1816
22. Cid J, Escolar G, Lozano M: Therapeutic efficacy of platelet components treated with amotosalen and ultraviolet A pathogen inactivation method: results of a meta-analysis of randomized controlled trials. Vox Sang 2012; 103:322-330
23. Perez-Pujol S, Tonda R, Lozano M, et al.: Effects of a new pathogen-reduction technology (Mirasol PRT) on functional aspects of platelet concentrates. Transfusion 2005; 45:911-919
24. Picker SM, Schneider V, Gathof BS: Platelet function assessed by shear-induced deposition of split triple-dose apheresis concentrates treated with pathogen reduction technologies. Transfusion 2009; 49:1224-1232
25. Polanowska-Grabowska R, Gear AR: High-speed platelet adhesion under conditions of rapid flow. Proc Natl Acad Sci USA 1992; 89:5754-5758
26. Topol EJ, Byzova TV, Plow EF: Platelet GPIIb-IIIa blockers. Lancet 1999; 353:227-231
27. Fressinaud E, Girma JP, Sadler JE, et al.: Synthetic RGDS-containing peptides of von Willebrand factor inhibit platelet adhesion to collagen. Thromb Haemost 1990; 64:589-593
28. Coene J, Devreese K, Sabot B, et al.: Paired analysis of plasma proteins and coagulant capacity after treatment with three methods of pathogen reduction. Transfusion 2014; 54:1321-1331
29. Ostrowski SR, Bochsen L, Salado-Jimena JA, et al.: In vitro cell quality of buffy coat platelets in additive solution treated with pathogen reduction technology. Transfusion 2010; 50:2210-2219
30. Nurden AT, Nurden P: The gray platelet syndrome: clinical spectrum of the disease. Blood Rev 2007; 21:21-36
31. Rendu F, Marche P, Maclouf J, et al.: Triphosphoinositide breakdown and dense body release as the earliest events in thrombin-induced activation of human platelets. Biochem Biophys Res Commun 1983; 116:513-519
32. Leytin V, Allen DJ, Mutlu A, et al.: Platelet activation and apoptosis are different phenomena: evidence from the sequential dynamics and the magnitude of responses during platelet storage. Br J Haematol 2008; 142:494-497
33. Picker SM, Steisel A, Gathof BS: Cell integrity and mitochondrial function after Mirasol-PRT treatment for pathogen reduction of apheresis-derived platelets: results of a three-arm in vitro study. Transfus Apher Sci 2009; 40:79-85
34. Li J, Lockerbie O, de Korte D, et al.: Evaluation of platelet mitochondria integrity after treatment with Mirasol pathogen reduction technology. Transfusion 2005; 45:920-926
35. Zharikov S, Shiva S: Platelet mitochondrial function: from regulation of thrombosis to biomarker of disease. Biochem Soc Trans 2013; 41:118-123
36. 2+ secretion. Blood 1981; 57:956-966
37. Johnson L, Loh YS, Kwok M, et al.: In vitro assessment of buffy-coat derived platelet components suspended in SSP+ treated with the INTERCEPT Blood system. Transfus Med 2013; 23:121-129
38. Prudent M, Crettaz D, Guignard J, et al.: Aggregation and proteomic analyses of intercept-treated platelets. Transfusion 2012; 52:63A.
39. Butler C, Doree C, Estcourt LJ, et al.: Pathogen-reduced platelets for the prevention of bleeding. Cochrane Database Syst Rev 2013; 3:CD009072